Roset Bm Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.

Naoki niikuraTokai university school of medicineDepartment of breast oncologyNational comprehensive cancer networkBreast oncologyTokai university schoolOnclive tvBreast cancerTrastuzumab deruxtecanT dxdHer2 positive breast cancerRoset bm study